quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 6, 2026

Atlassian targets 20%+ annual revenue growth through FY27 amid accelerating AI adoption and record enterprise expansion

View original at seekingalpha.com
Atlassian targets 20%+ annual revenue growth through FY27 amid accelerating AI adoption and record enterprise expansion Earnings Call Insights: Atlassian Corporation (TEAM) Q2 2026 MANAGEMENT VIEW * CEO Michael Cannon-Brookes opened the call stating "we closed out Q2 with very strong enterprise sales execution and incr…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Gross margin improvements continuing for third or fourth consecutive quarter while delivering 5 million Rovo seats

    80% confidence

  • Current pricing is delivering and customers' preferred payment method is still seat-based model

    80% confidence

  • Cloud migrations contributed mid-to-high single-digit impact to cloud revenue growth rates in Q2

    80% confidence

  • There is a ton of fear in the market right now on software

    80% confidence

  • Rovo surpassed 5 million monthly active users and AI is transforming how work gets done

    80% confidence

  • Atlassian closed out Q2 with very strong enterprise sales execution and surpassed $6 billion in annual run rate revenue

    80% confidence

  • Atlassian closed a record number of deals greater than $1 million ACV in Q2, nearly doubling year-over-year

    80% confidence

  • Customer conversations have changed a lot over the last year and customers are looking for strategic partners to help them through AI

    80% confidence

  • Data center segment expected to be down meaningfully next year

    80% confidence

  • Service collection is doing very well and is definitely Atlassian's fastest-growing product at significant scale

    80% confidence

  • No change to midterm outlook of 20%+ compounded annual revenue growth through FY27 and 25%+ non-GAAP operating margin in FY27

    80% confidence

  • Companies using AI codegen tools create 5% more tasks with Jira, have 5% higher monthly active users and expand Jira seats 5% faster

    80% confidence

  • Seat expansion is broad-based across both tech and non-tech users and remains stable

    80% confidence

  • Anthropic is a great partner of Atlassian, highlighting integration not competition

    80% confidence

  • More than 1,000 customers have upgraded to Teamwork Collection in less than 3 quarters, purchasing over 1 million seats

    80% confidence

  • Migrations expected to drive mid-to-high single-digit contribution to cloud revenue growth for full FY26

    80% confidence

  • Atlassian has confidence in long-term cloud guide and expects to tap into large market opportunities through enterprise AI and system of work strategies

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Atlassian targets 20%+ annual revenue growth through FY27 amid accelerating AI adoption and record enterprise expansion — Source | Via News | pt.VIA.NEWS